Mutual of Omaha Announces Approved Private Plan for Minnesota
Mutual of Omaha is launching its approved private insurance plan for Paid Family and Medical Leave (PFML) in Minnesota.
Mutual of Omaha's PFML private plan has been approved by the Minnesota's Department of Employment and Economic Development and meets all the necessary requirements. This PFML private program is part of Mutual of Omaha's ongoing commitment to providing exceptional insurance solutions tailored to the needs of businesses and their employees. Mutual of Omaha also offers PFML experts that can assist with leave and compliance questions.
'Our newly certified PFML plan reinforces Mutual of Omaha's dedication to supporting Minnesota employers and their workforce,' said Scott Ault, President, Workplace Solutions, at Mutual of Omaha. 'We are pleased to offer a private plan that matches the comprehensive benefits of the state program, while providing the added advantage of tailored coverage options.'
In Spring 2025, employers in Minnesota can opt for Mutual of Omaha's PFML private plan, which provides:
Comprehensive family and medical leave benefits
Flexible coverage options tailored to employer and employee needs
Dedicated customer support from Mutual of Omaha's experienced team
Mutual of Omaha currently offers PFML private plans in Massachusetts, Colorado, Oregon, Maine, New York and Delaware. For more information on Mutual of Omaha's PFML private plan and to explore coverage options, visit https://www.mutualofomaha.com/employer-based-plans/paid-family-medical-leave
Founded in 1909, Mutual of Omaha is a highly rated, Fortune 500 organization offering a variety of insurance and financial products for individuals, businesses and groups throughout the United States. As a mutual company, Mutual of Omaha is owned by its policyholders and committed to providing outstanding service to its customers. For more information about Mutual of Omaha, visit www.mutualofomaha.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
23 minutes ago
- Business Wire
Fal.Con 2025 Shatters Records for Growth, Attendance and Demand as CrowdStrike Leads Cybersecurity into the Agentic AI Era
AUSTIN, Texas--(BUSINESS WIRE)-- CrowdStrike (NASDAQ: CRWD) today announced record-breaking momentum for its flagship conference which has sold out faster than ever and is poised to deliver unprecedented growth across every key metric. From September 15 - 18, more than 8,000 attendees from over 65 countries and 25 industries will converge at the MGM Grand in Las Vegas. The event will host a record 110 partner sponsors and more than 3,000 leading organizations, positioning as the global stage for cybersecurity in the Agentic AI era. ' has become the premier industry conference for cybersecurity,' said Jennifer Johnson, chief marketing officer at CrowdStrike. 'We're not hosting a summit, we're leading a movement. The world's most influential leaders come to to advance cybersecurity into the AI era, build alliances, and harness the power of the Falcon platform to secure the organizations, economies and technologies shaping our future.' Now in its ninth year, will unite the world's top defenders, executives, and innovators to accelerate breakthroughs, forge industry-shaping partnerships, and set the strategic cybersecurity agenda for the year ahead. Under the 2025 theme 'Leading Cybersecurity into the Agentic AI Era,' attendees will experience visionary keynotes from CrowdStrike executives. As part of the 300+ session catalog, the program will feature 150+ customer and partner-led sessions from global leaders such as Charter Communications, Land O'Lakes, Mars Inc., Northwestern Mutual, St. Jude Children's Research Hospital, University of Michigan, Vail Resorts, and WeightWatchers. One, the conference's exclusive CxO program, will also convene 200+ leaders from the world's most innovative organizations for high-impact, closed-door discussions on the future of cybersecurity, the transformative role of AI, and strategies to outpace adversaries. 2025 will also showcase the unmatched strength of CrowdStrike's global partner ecosystem, welcoming more than 110 partner sponsors from across the cybersecurity landscape, the most in the conference's history. Premier sponsors AWS, Dell, and Intel will be joined by Diamond sponsors ExtraHop, Google Cloud, Okta, Rubrik, and Zscaler. Attendees can also register for full-day CrowdStrike University training courses to elevate their skills, sharpen their expertise, and advance their impact as defenders. The event begins on Monday, September 15, with CrowdStrike's annual Global Partner Summit, where more than 1,000 partner participants will unite to accelerate innovation, expand go-to-market opportunities, and drive joint success with the Falcon platform. Join the Action at Register to live stream the keynotes and access 80+ sessions on-demand following the event. Start planning now: Build your digital 2025 agenda here. About CrowdStrike CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world's most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data. Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting and prioritized observability of vulnerabilities. Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity and immediate time-to-value. CrowdStrike: We stop breaches. © 2025 CrowdStrike, Inc. All rights reserved. CrowdStrike and CrowdStrike Falcon are marks owned by CrowdStrike, Inc. and are registered in the United States and other countries. CrowdStrike owns other trademarks and service marks and may use the brands of third parties to identify their products and services.
Business Wire
23 minutes ago
- Business Wire
FLUMIST (Influenza, Vaccine Live, Intranasal), the nation's only nasal spray flu vaccine, now available for home delivery
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMIST ® (Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age. 1 Initially approved by the Food and Drug Administration (FDA) in 2003, this recent approval extends a safe and effective vaccination option for individuals and their families to help protect themselves during flu season with no needles or waiting rooms. Now, for the first time, eligible individuals and their families can help protect themselves during the 2025-26 flu season from the convenience of their own home. 2 Individuals 18 and older can visit to learn more and click to order, where they will be directed to complete a medical screening questionnaire. A licensed healthcare provider will review each submission to determine eligibility. Once eligibility is confirmed and insurance is verified, FLUMIST will be prescribed and shipped directly to the consumer's home on the date they had selected, complete with clear administration instructions, storage guidance and how to dispose. 1 Joris Silon, US Country President and Senior Vice President, AstraZeneca, said: 'The launch of FluMist Home is a transformational moment in the evolution of influenza protection, bringing a simple and accessible option directly into the hands of consumers. FluMist Home reflects the growing importance of direct-to-consumer offerings and underscores our commitment to continuous innovation, making it easier for people to get vaccinated and stay protected.' 3 According to the Centers for Disease Control and Prevention, the 2024-2025 influenza season was classified as a high-severity across all age groups in the US–the most severe since the 2009 H1N1 swine flu pandemic, resulting in at least 610,000 hospitalizations and 27,000 deaths. 4-6 These trends underscore the importance of increasing influenza vaccination coverage and providing more accessible vaccination options to help improve immunization rates for protection against flu. Ravi Jhaveri, MD, Division Head, Infectious Disease; Virginia H. Rogers Professor in Infectious Diseases, Professor of Pediatrics (Infectious Diseases), Northwestern University School of Medicine, Chicago, US, said: 'As influenza vaccination rates decline, especially among younger populations, this first-of-its-kind, at-home, needle-free option offers a critical opportunity to help make protection more accessible, convenient, and better aligned with the realities and current preferences of people's lives.' 7 Michele Slafkosky, Executive Director, Families Fighting Flu, said: 'Seasonal influenza can have a serious, even life-altering, impact on individuals and families, especially for those most vulnerable. Providing flexible vaccination options makes it easier for individuals and caregivers to help get protected. This can help to improve protection for individuals and strengthen collective immunity against influenza.' 8 Ami Patel, Executive Vice President, Hub Operations, ASPN Pharmacies, LLC, said: 'For the first time, consumers can receive and administer an influenza vaccine entirely at home—marking a historic shift in how preventive care is delivered. Through FluMist Home we're seeing a new model of care that puts consumers in control, offering a seamless, end-to-end experience, from determining eligibility to convenient home-delivery and administration. This milestone not only redefines convenience in vaccine delivery, but also sets the stage for a more accessible, patient-centered future in healthcare.' Through FluMist Home, all orders will be reviewed by a licensed healthcare provider with ASPN Pharmacies, an independent online specialty pharmacy, and then dispensed and shipped by Polaris Pharmacy Services, a specialty pharmacy, in temperature-controlled packages to maintain cold chain continuity. Consumers can select their preferred delivery date during the ordering process for added convenience. FLUMIST for self- or caregiver-administration is packaged in a consumer-friendly format with clear, at-home specific instructions that support proper handling, administration, and disposal. Once received, the vaccine should be stored in the refrigerator until use. The service also ensures documentation of vaccination in the relevant Immunization Information System. 1 For the 2025-26 flu season, FluMist Home will be available in 34 states covering about 80% of the eligible population. There are a number of states where FluMist Home is unavailable due to local pharmacy laws. Our aim is to have this service available in all 48 contiguous states in future seasons. FLUMIST will continue to be available in doctors' offices and pharmacies for administration by healthcare professionals across the nation. More information on FLUMIST and FluMist Home is available at Important Safety Information You should not get FLUMIST if you have a severe allergy to its components, eggs or other flu vaccines; or are 2 through 17 years old and take aspirin or medicines containing aspirin - children or adolescents should not be given aspirin for 4 weeks after getting FLUMIST unless your healthcare provider tells you otherwise Children under 2 years old have an increased risk of wheezing (difficulty with breathing) after getting FLUMIST Before getting FLUMIST, tell your healthcare provider about all your medical conditions, including if you: are currently wheezing; have a history of wheezing and are under 5 years of age; have asthma; have had Guillain-Barré syndrome (severe muscle weakness); have a weakened immune system or live with someone who has a severely weakened immune system; have problems with your heart, kidneys, or lungs; have diabetes; are pregnant or nursing; or are taking antiviral drugs for the treatment of influenza FLUMIST may cause rare but serious side effects including allergic reactions. Seek medical help right away if you experience any allergic reactions, including: hives; swelling of the face, lips, eyes, tongue or throat; throat tightness or trouble breathing The most common side effects are runny or stuffy nose, sore throat, and fever over 100 °F Approved Use FLUMIST is a vaccine that is sprayed into the nose to help protect against influenza in people ages 2 through 49 years. FLUMIST may not prevent influenza in everyone who gets vaccinated. Please see full Prescribing Information, including Patient Information and Instructions for Use. You may . Notes Influenza On average, about 8% of the US population becomes ill from influenza each season, with a range of between 3 percent and 11 percent, depending on the season. 8 During the 2024-2025 influenza season, an estimated 47 – 82 million people developed illness from influenza, 21 – 37 million visited a healthcare provider for influenza, with 610,000–1.3 million hospitalizations, and 27,000–130,000 deaths. 4 About FLUMIST Live Attenuated Influenza Vaccine FLUMIST is a live attenuated influenza vaccine (LAIV), which is administered as a nasal spray for the prevention of influenza. 9 FLUMIST is an Advisory Committee on Immunization Practices (ACIP) and American Academy of Pediatrics (AAP)-recommended influenza vaccine option. 10,11 FLUMIST was originally approved in the US in 2003 and since then almost 200 million doses have been distributed around the world. 2,3 FluMist Home State Availability Pharmacy laws vary state-by-state. For the 2025-2026 flu season, FluMist Home will be available in the following states: AL, AZ, CA, CO, CT, FL, GA, IA, ID, IL, MA, MD, ME, MI, MT, NC, ND, NE, NH, NJ, NV, OH, OR, PA, SC, SD, TN, TX, UT, VA, VT, WA, WI, and WY. For the 2025-2026 flu season. FluMist Home will not be available in: AK, AR, DC, DE, HI, IN, KS, KY, LA, MN, MO, MS, NM, NY, OK, RI, and WV. Our aim is to have this service available in all 48 contiguous states in future seasons. Human Factors Usability Study for FluMist Self-Administration FLUMIST for self- or caregiver-administration was approved by the FDA in September 2024, following research demonstrating that individuals over 18 years of age can safely and effectively self-administer or administer FLUMIST to eligible individuals. In FDA-required human factors/usability studies, AstraZeneca evaluated if individuals 18 through 49 years of age could appropriately administer FLUMIST when given instructions for use. The results showed that 100% of intended users successfully administered a full dose. 12 In addition, data show that efficacy, immunogenicity and adverse events with self-administration of FLUMIST are similar to those seen with HCP-administered vaccination. 13 The FLUMIST label has been updated to provide additional instructions on self and caregiver administration for eligible patients. Children 2-8 years of age with an uncertain vaccination history may not be eligible for caregiver administration and should consult their healthcare provider for further information. 9 AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit and follow the Company on social media @AstraZeneca. References FLUMIST Home Ordering, processing, and Disposal DoFP. REF-263898. US Food and Drug Administration (FDA). FDA approves nasal spray influenza vaccine for self- or caregiver administration. Accessed July 28, 2025. AstraZeneca. FluMist approved for self-administration in the US. Accessed July 28, 2025. US Centers for Disease Control and Prevention. Flu Burden. Preliminary estimated flu disease burden 2024-2025 flu season. Accessed July 28, 2025. US Centers for Disease Control and Prevention. Influenza (Flu) Past flu season severity assessments. Accessed July 22, 2025. US Centers for Disease Control and Prevention. 2024-2025 United States flu season: preliminary in-season severity assessment. Accessed June 10, 2025. US Centers for Disease Control and Prevention. FluVaxView Weekly Flu Vaccination Dashboard. Accessed July 31, 2025. US Centers for Disease Control and Prevention. About Influenza. . Accessed July 28, 2025. FLUMIST Prescribing Information. Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices — United States, 2024–25 influenza season. MMWR Recomm Rep. 2024;73(5):1–25. Recommendations for Prevention and Control of Influenza in Children, 2025–2026: Policy Statement. Pediatrics (2025) Bandell A, Araj E, Wu J. The role of human factors engineering in the FDA approval process for self-/caregiver-administration of live attenuated influenza vaccine. Presented at: National Immunization Conference, August 12-14, 2024, Atlanta, GA, USA. Burgess TH, Murray CK, Bavaro MF, et al. Self-administration of intranasal influenza vaccine: immunogenicity and volunteer acceptance. Vaccine
Business Wire
23 minutes ago
- Business Wire
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's Aspirina, the #1 pain relief option in Mexico 1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic consumers, Aspirina is poised to provide an accessible and effective solution for pain relief. Bayer's Aspirina, the #1 pain relief option in Mexico, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. Share As the Hispanic population in the U.S. continues to grow, currently representing 19 percent of the population and projected to reach 28 percent by 2060, Bayer Aspirin recognizes the importance of connecting with this vibrant community. The Aspirina pain relief option resonates deeply with cultural values and family traditions of those from Mexican and Latin American descent who have been using it as a long-standing pain relief option. 'Many Hispanic communities still face inadequate access to healthcare and consumer goods. As the fastest-growing demographic group in the U.S., the Hispanic population presents a unique opportunity for Bayer. By adding Aspirina to the U.S. portfolio, which has a strong equity in LATAM, we are placing the consumer at the center of our strategy. Data shows that 70 percent of Hispanic consumers feel a strong connection to their country of origin, making it essential for brands to honor and reflect this sentiment,' said Mohamed Atef, Global Brand Lead for Aspirin at Bayer. Many U.S. consumers of Hispanic origin grew up with Bayer's Aspirina— their parents and grandparents relied on it, instilling trust and nostalgia for the brand. Due to those deep connections, Aspirina has a 99 percent awareness rate in Mexico, with 67 percent of consumers using it regularly 2. With this inclusion in the U.S. market, we invite consumers to reconnect with a product that represents reliability, familiarity and their heritage. Bayer invented modern aspirin 125 years ago, and it's the most trusted aspirin brand for pain relief in the U.S. 3 Many pain reliever brands have come and gone over the last century, but Bayer® Aspirin continues to be one of the most trusted pain brands on the market. Aspirina is available at select Walmart and Walgreens, making it easy for families to find the pain relief they know. Join us in celebrating the launch of Aspirina in the U.S. and rediscover a brand that feels like home — a trusted companion in the journey of life. For more information on Aspirina visit About Aspirina For over 125 years, Bayer® Aspirin has been a leading aspirin brand in proven pain relief. Aspirina is a powerful pain reliever and fever reducer that contains 500 mg of the active ingredient aspirin (NSAID*). It provides fast and effective multi-symptom relief of headaches, muscle pain, toothaches, menstrual pain and minor arthritis pain for adults and children over 12, when used as directed. Aspirina is coated to make it easy to swallow and is free of caffeine. *nonsteroidal anti-inflammatory drug About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. 1 Based on volume sales in the last 52 weeks, via source: Grupo Knoblock/CID – Centro Integrador de Datos
